- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03689075
Extended Release Versus Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce Allosensitisation (EVITRA)
February 27, 2019 updated by: Imperial College London
Study to Compare Once-daily Extended Release Tacrolimus Versus Twice-daily Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce the Risk of Allosensitisation
Study to compare once-daily extended release tacrolimus versus twice-daily immediate release tacrolimus following renal allograft failure to reduce the risk of allosensitisation
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
64
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom, W12 0HS
- Recruiting
- Imperial College Healthcare NHS Trust
-
Contact:
- Michelle Willicombe
- Phone Number: 02083836641
- Email: imperial.evitra.study@nhs.net
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Able to give informed consent.
- Male or female, at least 18 years of age.
- Has renal allograft failure and is due to start haemodialysis therapy or within 28 days following starting dialysis.
- Has been already activated on the transplant wait list or is undergoing work up to be reactivated on the transplant list.
- Has no indication for graft nephrectomy at the time of transplant failure.
- Is receiving an immediate release tacrolimus maintenance immunotherapy regimen at the time of allograft failure.
Exclusion Criteria:
- Has another functioning organ transplanted (eg. pancreas, liver, cardiac) at the time of kidney allograft failure.
- Allograft failure within a month of transplant.
- Patients who are due to receive or receiving peritoneal dialysis following graft failure.
- Patients with detectable DSA at the time of allograft failure
- Receiving an extended release preparation of tacrolimus as immunotherapy at the time of graft failure.
- Requires continuation of maintenance immunosuppression other than prednisolone or tacrolimus (eg. Mycophenolate mofetil or sirolimus).
- Patients who on IR-FK conversion would require less than 0.75mg of Envarsus.
- HLA type of donor is unknown.
- Has a history of, or active co-morbidity that in the Investigator's opinion, could affect the conduct of the study.
- Has any condition at the time of recruitment which would prohibit or pose a relative contraindication for the continued use of tacrolimus to a target trough level of between 3-5ng/ml
- Active bacterial, viral (including CMV and EBV) or parasitic infections, including tuberculosis that, in the Investigator's opinion, could affect the conduct of the study.
- Has active malignancy.
- Female patients of child bearing age, who wish to consider pregnancy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Immediate release tacrolimus
Patients will continue on immediate release tacrolimus
|
|
Active Comparator: Extended release tacrolimus
|
Patients will be randomised to receive either envarsus or to continue on an immediate release tacrolimus formulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of de novo allosensitisation (donor specific antibodies) at 24 months post allograft failure.
Time Frame: 24 months
|
Number of patients who develop new DSA in each group
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medication adherence measurement
Time Frame: 24 months
|
Will be measured by BAASIS questionnaire (comparison of scores)
|
24 months
|
Health-Related Quality of Life measurement
Time Frame: 24 months
|
Will be measured by the EQ-5D-5L Questionnaire (comparison of scores) - 5D - 5L Questionnaire |
24 months
|
Coefficient of variation of tacrolimus levels at 24 months post allograft failure.
Time Frame: 24 months
|
Incorporating all study visit trough tacrolimus levels (standard deviation/mean)
|
24 months
|
Adverse events
Time Frame: 24 months
|
Incidence of infective episodes, malignancy, diabetes, erythropoietin resistance, graft nephrectomy
|
24 months
|
Chances of re-transplantation as determined by the transplant matchability calculator available from NHSBT
Time Frame: 24 months
|
Will be calculated by using the NHSBT calculator
|
24 months
|
Proportion of patients retransplanted during the study period
Time Frame: 24 months
|
Proportion of patients in each arm receiving a transplant
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2018
Primary Completion (Anticipated)
November 1, 2021
Study Completion (Anticipated)
November 1, 2023
Study Registration Dates
First Submitted
September 20, 2018
First Submitted That Met QC Criteria
September 24, 2018
First Posted (Actual)
September 28, 2018
Study Record Updates
Last Update Posted (Actual)
February 28, 2019
Last Update Submitted That Met QC Criteria
February 27, 2019
Last Verified
February 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18IC4423
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immunosuppression
-
Linda CendalesRecruitingImmunosuppressionUnited States
-
Erasmus Medical CenterCompleted
-
Hospices Civils de LyonWithdrawn
-
Weill Medical College of Cornell UniversityTerminatedImmunosuppressionUnited States
-
University of PittsburghNovartis PharmaceuticalsCompletedImmunosuppressionUnited States
-
Edward GeisslerChiesi Pharmaceuticals GmbHRecruiting
-
Children's Hospital of PhiladelphiaEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingImmunosuppressionUnited States
-
University of FloridaTerminatedImmunosuppressionUnited States
-
University of PittsburghNovartis PharmaceuticalsCompletedImmunosuppressionUnited States
-
Chong Kun Dang PharmaceuticalCompletedImmunosuppressionKorea, Republic of
Clinical Trials on Envarsus Oral Product
-
University of AlbertaRecruitingCardiovascular Diseases | Renal Insufficiency | Metabolic Syndrome | Liver Transplant; Complications | Immunosuppressant Adverse ReactionCanada
-
Instituto do Cancer do Estado de São PauloRecruitingHepatocellular Carcinoma | Liver CancerBrazil
-
UAS Labs LLCCompleted
-
University Hospital, BordeauxCompleted
-
St George's, University of LondonRecruitingChronic Kidney Diseases | Heart Failure With Reduced Ejection Fraction | Hyperkalemia | ACE Inhibitor Induced Hyperkalaemia | Mineralocorticoid Resistant HyperkalemiaUnited Kingdom
-
Brigham and Women's HospitalUnknownChronic Kidney Diseases | HyperkalemiaUnited States
-
Peking Union Medical College HospitalUnknown
-
Xenon Pharmaceuticals Inc.CompletedHealthy VolunteersUnited Kingdom
-
Duke UniversityVifor PharmaCompletedEnd Stage Renal Disease | HyperkalemiaUnited States
-
National Cheng Kung UniversityNational Cheng-Kung University Hospital; Ministry of Science and Technology...Recruiting